CA2723698C - Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis - Google Patents

Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis Download PDF

Info

Publication number
CA2723698C
CA2723698C CA2723698A CA2723698A CA2723698C CA 2723698 C CA2723698 C CA 2723698C CA 2723698 A CA2723698 A CA 2723698A CA 2723698 A CA2723698 A CA 2723698A CA 2723698 C CA2723698 C CA 2723698C
Authority
CA
Canada
Prior art keywords
subjects
ctla4
seq
arthritis
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2723698A
Other languages
English (en)
French (fr)
Other versions
CA2723698A1 (en
Inventor
George Vratsanos
Jean-Claude Becker
Michael Corbo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41264941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2723698(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2723698A1 publication Critical patent/CA2723698A1/en
Application granted granted Critical
Publication of CA2723698C publication Critical patent/CA2723698C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CA2723698A 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis Active CA2723698C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5033608P 2008-05-05 2008-05-05
US61/050,336 2008-05-05
US12/387,359 2009-05-01
US12/387,359 US7915222B2 (en) 2008-05-05 2009-05-01 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
PCT/US2009/042761 WO2009137424A1 (en) 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Publications (2)

Publication Number Publication Date
CA2723698A1 CA2723698A1 (en) 2009-11-12
CA2723698C true CA2723698C (en) 2018-03-06

Family

ID=41264941

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2723698A Active CA2723698C (en) 2008-05-05 2009-05-05 Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Country Status (25)

Country Link
US (3) US7915222B2 (enExample)
EP (2) EP2279206B1 (enExample)
JP (1) JP2011522795A (enExample)
KR (1) KR20110014180A (enExample)
CN (1) CN102037010A (enExample)
AR (1) AR071672A1 (enExample)
AU (1) AU2009244448B2 (enExample)
BR (1) BRPI0912249A2 (enExample)
CA (1) CA2723698C (enExample)
CL (1) CL2009001082A1 (enExample)
DK (1) DK2279206T3 (enExample)
EA (1) EA201001749A1 (enExample)
ES (1) ES2539840T3 (enExample)
HK (1) HK1208230A1 (enExample)
HR (1) HRP20150552T1 (enExample)
HU (1) HUE025256T2 (enExample)
IL (1) IL208691A (enExample)
MX (1) MX2010011503A (enExample)
NZ (1) NZ589020A (enExample)
PL (1) PL2279206T3 (enExample)
PT (1) PT2279206E (enExample)
SI (1) SI2279206T1 (enExample)
TW (2) TWI454278B (enExample)
WO (1) WO2009137424A1 (enExample)
ZA (1) ZA201007914B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
CA2851322C (en) * 2011-10-10 2020-03-31 Medimmune Limited Treatment for rheumatoid arthritis with gm csfr alpha antibodies
US20140006055A1 (en) * 2012-06-27 2014-01-02 Iagnosis, Inc. Integrated Medical Evaluation and Record Keeping System
US20150232558A1 (en) * 2012-10-30 2015-08-20 Emory University Stimulating bone formation by inhibition of cd28 co-stimulation
WO2014151230A2 (en) * 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Method of treating granulomatosis with polyangiitis
US20170042972A1 (en) * 2014-04-25 2017-02-16 Chetan KARYEKAR Use of ctla4 compound for achieving drug-free remission in subjects with early ra
CN121159719A (zh) 2015-04-17 2025-12-19 高山免疫科学股份有限公司 具有可调的亲和力的免疫调节蛋白
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CN110148465B (zh) * 2019-05-10 2023-07-04 中山大学孙逸仙纪念医院 一种用于分析类风湿性关节炎的系统
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
CA2580812A1 (en) 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctla4 receptor, fusion proteins containing it and uses thereof
US6090914A (en) 1991-06-27 2000-07-18 Bristol-Myers Squibb Company CTLA4/CD28Ig hybrid fusion proteins and uses thereof
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
CA2154487A1 (en) * 1993-01-21 1994-08-04 Nicholas S. Hill Vaccines and methods for preventing and treating fescue toxicosis in herbivores
US5773253A (en) 1993-01-22 1998-06-30 Bristol-Myers Squibb Company MYPPPY variants of CTL A4 and uses thereof
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
EP0892643B2 (en) 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
ZA98533B (en) 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
US20030219863A1 (en) 1997-01-31 2003-11-27 Bristol-Myers Squibb Company Soluble CTLA4 mutant molecules and uses thereof
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA02012157A (es) 2000-06-09 2003-06-06 Bristol Myers Squibb Co Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
EP1935427B1 (en) * 2000-07-03 2018-03-07 Bristol-Myers Squibb Company Uses of soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2436139A1 (en) 2001-01-26 2002-08-01 Emory University Methods of inducing organ transplant tolerance and correcting hemoglobinopathies
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
MXPA05006522A (es) 2002-12-23 2006-02-17 Bristol Myers Squibb Co Mejora en la calidad de producto en procesos de cultivo en celulas de mamiferos para la produccion de proteina.
MXPA05006523A (es) 2002-12-23 2005-08-26 Squibb Bristol Myers Co Procesos de cultivo de celulas de mamiferos para la produccion de proteinas.
SG144925A1 (en) 2003-08-04 2008-08-28 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble ctla4 molecule
US7930013B2 (en) 2005-06-29 2011-04-19 Compumedics Limited Sensor assembly with conductive bridge
EP1933777B1 (en) * 2005-08-22 2017-06-14 Incept, LLC Flared stents and apparatus for using them
US8476239B2 (en) 2005-12-20 2013-07-02 Bristol-Myers Squibb Company Stable protein formulations
DK1969007T3 (da) 2005-12-20 2013-11-25 Bristol Myers Squibb Co Sammensætninger og fremgangsmåder til fremstilling af en sammensætning
US7528111B2 (en) 2006-05-12 2009-05-05 Bristol-Myers Squibb Company Method of vaccinating subjects receiving immune modulating therapy
US7915222B2 (en) * 2008-05-05 2011-03-29 Bristol-Myers Squibb Company Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis

Also Published As

Publication number Publication date
PT2279206E (pt) 2015-07-27
AR071672A1 (es) 2010-07-07
NZ589020A (en) 2012-05-25
CA2723698A1 (en) 2009-11-12
DK2279206T3 (en) 2015-07-27
IL208691A0 (en) 2010-12-30
AU2009244448A1 (en) 2009-11-12
PL2279206T3 (pl) 2015-09-30
WO2009137424A1 (en) 2009-11-12
EP2279206B1 (en) 2015-04-22
US7915222B2 (en) 2011-03-29
CN102037010A (zh) 2011-04-27
TW201444575A (zh) 2014-12-01
US20090280119A1 (en) 2009-11-12
TWI454278B (zh) 2014-10-01
JP2011522795A (ja) 2011-08-04
US9012408B2 (en) 2015-04-21
EP2279206A1 (en) 2011-02-02
IL208691A (en) 2015-01-29
EA201001749A1 (ru) 2011-06-30
CL2009001082A1 (es) 2010-02-12
EP2279206A4 (en) 2011-05-25
AU2009244448B2 (en) 2014-07-31
US20130195865A1 (en) 2013-08-01
ZA201007914B (en) 2011-07-27
EP2891665A1 (en) 2015-07-08
SI2279206T1 (sl) 2015-08-31
HUE025256T2 (en) 2016-02-29
HK1208230A1 (en) 2016-02-26
HRP20150552T1 (hr) 2015-06-19
BRPI0912249A2 (pt) 2015-10-20
ES2539840T3 (es) 2015-07-06
TW200948381A (en) 2009-12-01
MX2010011503A (es) 2010-11-09
HK1148291A1 (en) 2011-09-02
US20110142835A1 (en) 2011-06-16
KR20110014180A (ko) 2011-02-10
US8435952B2 (en) 2013-05-07

Similar Documents

Publication Publication Date Title
CA2723698C (en) Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
US10052360B2 (en) Methods for treating dermatomyositis or polymyositis by administering a soluble CTLA4 molecule
US20200069772A1 (en) Methods of treating early rheumatoid arthritis
WO2003088991A9 (en) Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid
AU2014213571B2 (en) Method of preventing the development of rheumatoid arthritis in subjects with un-differentiated arthritis
HK1148291B (en) Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
WO2014151230A2 (en) Method of treating granulomatosis with polyangiitis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140327

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250402

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401